Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy

Urology

Volumn 47, Issue 1 SUPPL. 1, 1996, Pages 54-60

  Schellhammer, Paul ^a   Sharifi, Roohollah ^b   Block, Norman ^c   Soloway, Mark ^c   Venner, Peter ^e   Patterson, A Lynn ^d   Sarosdy, Michael ^f   Vogelzang, Nicholas ^g   Jones, Julie ^h   Kolvenbag, Geert ^h  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TENNESSEE   (United States)

^e CROSS CANCER INSTITUTE   (Canada)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; PLACEBO;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 9044231766     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(96)80010-0     Document Type: Article

References (22)

1. Kaisary AV: Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate 5 (suppl): 27-33, 1994.
2. Iversen P: Update of monotherapy trials with the new antiandrogen, Casodex (ICI 176,334). Eur Urol 26 (suppl 1): 5-9, 1994.
3. Pienta PJ, and Esper PS: Risk factors for prostate cancer. Ann Intern Med 118: 793-803, 1993.
4. Bracci U, and Di Silverio F: Role of cyproterone acetate in urology, in Martini L and Motta M (Eds): Androgens and Antiandrogens. New York, Raven Press, 1977, pp 333-339.
5. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Edmond JP, Fazekas ATA, Raynaud JP, and Husson JM: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5: 267-275, 1982.
6. Gittes RF: Carcinoma of the prostate. N Engl J Med 324: 236-245, 1991.
7. Walsh PC: Benign and malignant neoplasms of the prostate. J Urol 147: 289-290, 1992.
8. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
9. Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, and Dorr FA: Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66: 1039-1040, 1990.
10. Denis L, Smith PH, Carneiro De Moura JL, Newling DWW, Bono A, Keuppens F, Robinson M, Mahler C, Sylvester R, De Pauw M, Vermeylen K, Ongena P, and members of the EORTC GU Group: Orchiectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. Eur Urol 18 (suppl 3): 34-40, 1990.
11. Keuppens F, Denis L, Smith PH, Pinto Carvalho A, Newling DWW, Bono A, Sylvester R, De Pauw M, Vermeylen K, Ongena P, and the EORTC GU Group: Zoladex and flutamide versus bilateral orchiectomy: a randomized phase III EORTC 30853 study. Cancer 66: 1045-1057, 1990.
12. Denis LJ, Cameiro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, and Depauw M: Goserelin acetate and flutamide versus bilateral orchiectomy: a Phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42: 119-130, 1993.
13. Keuppens F, Whelan P, Carneiro de Moura JL, Newling DWW, Bono A, Denis L, Robinson M, Mahler C, Sylvester R, De Pauw M, Vermeylen K, Ongena P, and the members of the European Organization for Research and Treatment of Cancer Genitourinary Group: Orchiectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). Cancer 72: 3863-3869, 1993.
14. Newling DWW, Denis L, Vermeylen K, for the European Organization for Research and Treatment of Cancer - Genitourinary Group: Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 72: 3793-3798, 1993.
15. Bertagna C, De Gery A, Hucher M, Francois JP, and Zanirato J: Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 73: 396-402, 1994.
16. Furr BJ: "Casodex" (ICI 176,334) - a new, pure peripherally-selective anti-androgen: preclinical studies. Horm Res 32 (suppl 1): 69-76, 1989.
17. Delaere KP, and Van Thillo EL: Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 18: 13-18, 1991.
18. Lundgren R: Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 59: 156-158, 1987.
19. Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP, and Sotarauta M: A multicentre randomized trial comparing Zoladex with Zoladex + flutamide in the treatment of advanced prostate cancer (survival update), in Murphy G, Khoury S, Chatelain C, and Denis L (Eds): Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Channel Islands, Scientific Communication International, Ltd., 1992.
20. Iversen P, Christensen MG, Friis E, Hornbol P, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P, et al.: A phase III trial of Zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66 (suppl 5): 1058, 1990.
21. Boccardo F, Decensi A, Guameri D, Rubagotti A, Oneto F, Martorana G, Giuliani L, Delli Ponti U, Petracco S, and Cortellini P: Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Eur Urol 18 (suppl 3): 48-53, 1990.
22. Boccon-Gibod L, Fournier G, Bottet P, and Mallo C. Flutamide versus orchidectomy in patients with metastatic prostatic carcinoma. (Abstr. 818.) J Urol 147: 417A, 1992.